Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 87. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 20192422
Neurological associations of COVID-191450
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series944
Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?747
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts673
Challenges in the diagnosis of Parkinson's disease506
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches417
Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches411
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group408
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation376
Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues315
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis313
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria285
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial275
Myelin-oligodendrocyte glycoprotein antibody-associated disease268
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias264
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial233
New insights into atypical Alzheimer's disease in the era of biomarkers230
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study230
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study223
Traumatic brain injury: progress and challenges in prevention, clinical care, and research219
Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia211
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial206
Remyelination in multiple sclerosis: from basic science to clinical translation194
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study186
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial182
Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study181
Long-term unsupervised mobility assessment in movement disorders181
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study178
The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data176
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study163
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-cont162
A case of probable Parkinson's disease after SARS-CoV-2 infection161
Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease157
An Italian programme for COVID-19 infection in multiple sclerosis157
Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation152
The neuropsychiatry of Parkinson's disease: advances and challenges148
Progress towards therapies for disease modification in Parkinson's disease145
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis141
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials140
30 years of second-generation antiseizure medications: impact and future perspectives139
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial137
Monogenic variants in dystonia: an exome-wide sequencing study136
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis133
Multiple sclerosis progression: time for a new mechanism-driven framework131
Functional neurological disorder: new subtypes and shared mechanisms127
Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts125
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial122
Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis120
PET imaging of neuroinflammation in neurological disorders120
Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial120
Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder119
Post-viral effects of COVID-19 in the olfactory system and their implications119
Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study118
Neuroimaging standards for research into small vessel disease—advances since 2013116
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial116
Neuromodulation in epilepsy: state-of-the-art approved therapies115
COVID-19 related stroke in young individuals114
Evidence-based support for autistic people across the lifespan: maximising potential, minimising barriers, and optimising the person–environment fit113
Moyamoya disease: diagnosis and interventions113
Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised contr112
Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial110
Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study110
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how109
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities108
Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care106
Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies103
Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis103
Alzheimer's disease associated with Down syndrome: a genetic form of dementia103
Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies102
Forecasting seizure risk in adults with focal epilepsy: a development and validation study102
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, 100
Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances99
Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective97
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment97
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial96
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study96
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial96
Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study96
SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy95
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial94
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials94
Brain injury after cardiac arrest: from prognostication of comatose patients to rehabilitation91
Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial91
Ageing without dementia: can stimulating psychosocial and lifestyle experiences make a difference?90
Mitochondrial disease in adults: recent advances and future promise89
Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population-based cohort study87
Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled st87
0.076670169830322